Rhythm Biosciences (FRA:0RY) Total Operating Expense: €4.45 Mil (TTM As of Dec. 2025)


FRA:0RY Rhythm Biosciences Ltd FRA:0RY
31 GF Score
Price €0.06
! 5 Warning Signs
View Full Analysis

What is Rhythm Biosciences Total Operating Expense?

Rhythm Biosciences FRA:0RY 31 Total Operating Expense is €4.45 Mil as of Dec. 2025. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

Rhythm Biosciences's Total Operating Expense for the six months ended in Dec. 2025 was €2.09 Mil. Rhythm Biosciences's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €4.45 Mil.

Rhythm Biosciences Total Operating Expense Related Terms

Rhythm Biosciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Total Operating Expense Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial 4.91 7.48 7.15 3.42 3.78

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 1.71 1.52 2.36 2.09
FRA:0RY
31GF Score
Rhythm Biosciences Ltd FRA:0RY
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Biosciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €4.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €4.45 Mil mean?
Rhythm Biosciences (FRA:0RY) has a Total Operating Expense of €4.45 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Rhythm Biosciences and its competitors.
Is Rhythm Biosciences' Total Operating Expense too high?
Rhythm Biosciences' current Total Operating Expense is €4.45 Mil. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Total Operating Expense compare to TMO and DHR?
Rhythm Biosciences' Total Operating Expense of €4.45 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Diagnostics & Research company?
A good Total Operating Expense depends on the Medical Diagnostics & Research industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Rhythm Biosciences and its competitors. Rhythm Biosciences's current Total Operating Expense is €4.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Total Operating Expense of €4.45 Mil. The current Total Operating Expense is €4.45 Mil. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Total Operating Expense is €4.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score

Get the complete analysis for FRA:0RY

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price